-
UPDATE: Citadel Securities Initiates Coverage on Biogen Idec
Monday, August 8, 2011 - 7:58am | 106Citadel Securities has published a report on Biogen Idec Inc (NASDAQ: BIIB) intiating coverage on the biotech company. In the report, Citadel Securities wrote, "Biogen's hemophilia pipeline may provide an additional high-margin growth driver, in our view, although we await final data expected in...
-
UPDATE: Citadel Securities Initiates Coverage on Human Genome Sciences
Monday, August 8, 2011 - 7:51am | 89Citadel Securities has published a report on Human Genome Sciences (NASDAQ: HGSI) initiating coverage on the biotech company. In the report, Citadel wrote, "We believe investors and the Street are singularly focused on Benlysta, resulting in the opportunity for potential upside on the “hidden...
-
Jefferies Reiterates Buy on Vanda Pharmaceuticals, Reduces PT to $8.50
Monday, August 8, 2011 - 7:46am | 47Jefferies reiterated its Buy rating on Vanda Pharmaceuticals (NASDAQ: VNDA). At the same time, the rating agency reduced its price target on the company's stock from $10 to $8.50. On Friday, VNDA lost 0.44% of its value to finish the day at $6.75.
-
UPDATE: Citadel Securities Initates Coverage on Dendreon
Monday, August 8, 2011 - 7:19am | 83Citadel Securities has published a report on Dendreon (NASDAQ: DNDN) initiating coverage of the biotech company. In the report, Citadel Securities wrote, "We expect competitor data from Johnson & Johnson's oral prostate cancer drug ZYTIGA to be available during 2012, with an interim look...
-
UPDATE: Citadel Securities Initiates Coverage on Vertex
Monday, August 8, 2011 - 7:04am | 85Citadel Securities has published a report on Vertex (NASDAQ: VRTX) initiating coverage on the medicine developer. In the report, Citadel Securities wrote, "We are initiating coverage of Vertex Pharmaceuticals (VRTX) with a Neutral rating and $46 price target. While the launch of Incivek for HCV is...
-
Bank of America Lowers PO On Amylin Pharmaceuticals To $15
Monday, August 8, 2011 - 6:59am | 28Bank of America has lowered the price objective on Amylin Pharmaceuticals (NASDAQ: AMLN) from $16 to $15 and maintains its Neutral rating.
-
UPDATE: Citadel Securities Initiates Coverage on Seattle Genetics
Monday, August 8, 2011 - 6:56am | 101Citadel has published a report on Seattle Genetics (NASDAQ: SGEN) initiating coverage on the biotech company. In the report, Citadel wrote, "Despite our bearish view on the Adcetris market opportunity, we believe the product is approvable based on Phase II data. While we believe approval could be...
-
Jefferies Lowers PT On Vanda Pharmaceuticals To $8.50
Monday, August 8, 2011 - 6:46am | 27Jefferies & Company has lowered the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) from $10 to $8.50 and maintains its Buy rating.
-
Citadel Initiates Seattle Genetics At Reduce, $10 PT
Monday, August 8, 2011 - 6:08am | 24Citadel Securities has initiated coverage on Seattle Genetics (NASDAQ: SGEN) with a Reduce rating and $10 PT.
-
Citadel Initiates Vertex Pharmaceuticals At Neutral, $46 PT
Monday, August 8, 2011 - 6:07am | 25Citadel Securities has initiated coverage on Vertex Pharmaceuticals (NASDAQ: VRTX) with a Neutral rating and $46 price target.
-
Citadel Initiates Dendreon At Neutral, $10 PT
Monday, August 8, 2011 - 6:05am | 24Citadel Securities has initiated coverage on Dendreon (NASDAQ: DNDN) with a Neutral rating and $10 price target.
-
Citadel Initiates Human Genome Sciences With Add Rating, $25 PT
Monday, August 8, 2011 - 6:02am | 26Citadel Securities has initiated coverage on Human Genome Sciences (NASDAQ: HGSI) with an Add rating and $25 price target.
-
Citadel Initiates Biogen Idec With Add Rating, $130 PT
Monday, August 8, 2011 - 6:01am | 25Citadel Securities has initiated coverage on Biogen Idec (NASDAQ: BIIB) with an Add rating and $130 price target.
-
Earnings Scheduled For August 8
Monday, August 8, 2011 - 3:50am | 413Dollar Thrifty Automotive Group Inc (NYSE: DTG) is projected to report its Q2 EPS at $1.37 on revenue of $408.57 million. MGM Resorts International (NYSE: MGM) is projected to report a FQ4 loss at $0.13 per share on revenue of $1.59 billion. 99 Cents Only Stores (NYSE: NDN) is expected to...
-
Calls Purchased on Savient Pharmaceuticals
Friday, August 5, 2011 - 2:47pm | 124Shares of Savient Pharmaceuticals (NASDAQ: SVNT) are lower on the session by 3.25%, currently trading at $4.46. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average. Options traders are buying calls on the name today. A short...